News | Published:

Radioactive drugs emerge from the shadows to storm the market

Nature Biotechnology volume 36, pages 11251127 (2018) | Download Citation

Subjects

This article has been updated

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Change history

  • 18 December 2018

    In the version of this article initially published, the descriptions of Actinium Pharmaceuticals' Iomab-B and Nordic Nanovector's 177Lu-lilotomab satetraxetan (Betalutin) were reversed. Iomab-B uses iodine-131 to destroy the bone marrow ahead of stem cell transplantation and Betalutin directs lutetium-177 to CD45-expressing B cells in follicular lymphoma. The error has been corrected in the HTML and PDF versions of the article.

  • 18 January 2019

    In the version of this article initially published, Betalutin was described as directing a radioisotope to CD45-expressing B cells; in fact, it directs it to CD37-expressing B cells. The error has been corrected in the HTML and PDF versions of the article.

Author information

Affiliations

  1. Somerville, Massachusetts

    • Elie Dolgin

Authors

  1. Search for Elie Dolgin in:

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt1218-1125

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing